Generic drugmaker Aurobindo Pharma’s shares ended more than 3% lower on Tuesday in the backdrop of U.S. Food and Drug Administration issuing an establishment inspection report with a voluntary action indicated (VAI) classification to subsidiary Apitoria Pharma’s active pharmaceutical ingredient plant near Hyderabad.
The U.S. FDA inspection of Unit-2, the API manufacturing facility of Apitoria Pharma in Jinnaram Mandal, Sanga Reddy district, conducted from September 23-27, had concluded with the regulator issuing 10 observations.
The unit has since received an EIR classifying the facility as VAI, the parent company said in a filing. Aurobindo Pharma shares closed 3.19% lower at ₹1,137.75 each on the BSE.
Published – January 28, 2025 07:48 pm IST